Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ropesalazine
- Development stage
- Unknown
- Lead developer
- GNT Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ropesalazine (INN: crisdesalazine) is a multi-target small molecule investigational drug developed by GNT Pharma for the treatment of neurodegenerative diseases. It is designed to address two primary pathological drivers: neuroinflammation and oxidative stress. Ropesalazine acts as a selective inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1), which reduces the production of the pro-inflammatory mediator PGE2, and functions as a potent scavenger of free radicals. By mitigating these processes, the drug aims to prevent nerve cell death and the formation of amyloid plaques and neurofibrillary tangles. It is currently marketed in South Korea as GedaCure for canine cognitive dysfunction syndrome (CDS) and is in Phase II clinical development for human Alzheimer's disease.
- Brand names
- GedaCure
- Other names
- crisdesalazine
02
Targets
PTGES (Microsomal prostaglandin E synthase-1)
Beyond the preview
Go deeper on ropesalazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ropesalazine.